| Literature DB >> 25510736 |
Rieko Okada1, Akira Okada, Takashi Okada, Mamoru Nanasato, Kenji Wakai.
Abstract
BACKGROUND: The associations between visit-to-visit blood pressure (BP) variability and cardiac function and carotid atherosclerosis is not clear.Entities:
Mesh:
Year: 2014 PMID: 25510736 PMCID: PMC4273455 DOI: 10.1186/1471-2261-14-188
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Characteristics of subjects according to the level of blood pressure variability (n = 144)
| Blood pressure variability | ||||
|---|---|---|---|---|
| Low variability | Middle variability | High variability | P value | |
| n | 48 | 48 | 48 | |
| Age (years) | 72.3 ± 9.1 | 70.8 ± 8.5 | 74.7 ± 8.7 | 0.101a |
| Male | 24 (50.0%) | 21 (43.8%) | 19 (39.6%) | 0.586b |
| Blood pressure measurements (times) | 9.1 ± 3.1 | 9.5 ± 2.6 | 9.7 ± 2.8 | 0.569a |
| Systolic blood pressure (mmHg) | 130.2 ± 10.1 | 132.0 ± 12.2 | 131.5 ± 16.9 | 0.801a |
| Diastolic blood pressure (mmHg) | 72.1 ± 11.0 | 72.8 ± 11.8 | 71.2 ± 10.3 | 0.780a |
| Pulse pressure (mmHg) | 58.1 ± 12.3 | 59.2 ± 11.5 | 60.3 ± 15.4 | 0.728a |
| Heart rate (beats/min) | 73.8 ± 9.8 | 70.5 ± 6.8 | 72.3 ± 6.9 | 0.248a |
| Antihypertensive medication | 33 (68.8%) | 38 (79.2%) | 41 (85.4%) | 0.140b |
| Calcium-channel blocker | 27 (56.3%) | 30 (62.5%) | 34 (70.8%) | 0.331b |
| Renin-angiotensin antagonist | 20 (41.7%) | 19 (39.6%) | 24 (50.0%) | 0.553b |
| β-blocker | 6 (12.5%) | 9 (18.8%) | 3 (6.3%) | 0.180b |
| Fasting plasma glucose (mg/dL) | 116.3 ± 41.5 | 118.8 ± 47.8 | 115.5 ± 38.9 | 0.923a |
| HbA1c (%) | 6.12 ± 0.94 | 5.98 ± 0.80 | 5.82 ± 0.60 | 0.173a |
| Glucose-lowering medication | 8 (16.7%) | 8 (16.7%) | 8(16.7%) | 1.000b |
| LDL-cholesterol (mg/dl) | 114.2 ± 24.0 | 118.0 ± 28.2 | 124.6 ± 25.5 | 0.146a |
| Lipid-lowering medication | 13 (27.1%) | 16 (33.3%) | 17 (35.4%) | 0.660b |
| Uric acid (mg/dL) | 5.50 ± 1.26 | 5.25 ± 1.29 | 5.38 ± 1.32 | 0.643a |
| Body mass index (kg/m2) | 24.13 ± 3.87 | 24.03 ± 3.20 | 24.19 ± 3.56 | 0.977a |
| eGFR (ml/min/1.73 m2) | 68.0 ± 19.4 | 67.5 ± 15.9 | 64.9 ± 17.8 | 0.667a |
| Proteinuria | 4 (8.3%) | 6 (12.5%) | 7 (14.6%) | 0.627b |
| Cardiovascular disease | 9 (18.8%) | 8 (16.7%) | 7 (14.6%) | 0.861b |
Data are means ± standard deviation or n (%). Low, middle, and high variability are defined as the lowest (<8.29 mmHg), middle (8.29–10.99 mmHg), and highest (>10.99 mmHg) tertiles of the standard deviation of systolic blood pressure, respectively.
LDL-cholesterol, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.
aAnalysis of covariance; bχ2 test.
Echocardiography, and cervical ultrasonography characteristics of subjects according to the level of blood pressure variability (n = 144)
| Blood pressure variability | ||||
|---|---|---|---|---|
| Low variability | Middle variability | High variability | P value a | |
| n | 48 | 48 | 48 | |
| Left atrium diameter (mm) | 37.3 ± 5.0 | 36.4 ± 4.6 | 37.6 ± 6.2 | 0.541 |
| E (m/s) | 0.53 ± 0.13 | 0.59 ± 0.19 | 0.57 ± 0.20 | 0.162 |
| A (m/s) | 0.71 ± 0.15 | 0.77 ± 0.17 | 0.77 ± 0.19 | 0.153 |
| e’ (m/s) | 0.054 ± 0.019 | 0.053 ± 0.012 | 0.048 ± 0.019 | 0.189 |
| E/A | 0.77 ± 0.26 | 0.80 ± 0.29 | 0.76 ± 0.29 | 0.845 |
| E/e’ | 10.66 ± 3.30 | 11.60 ± 3.36 | 13.03 ± 5.33 | 0.019 |
| LVMI (mm) | 139.0 ± 27.3 | 137.0 ± 23.6 | 148.1 ± 30.7 | 0.108 |
| Ejection fraction (%) | 58.3 ± 9.1 | 58.2 ± 6.8 | 57.5 ± 8.1 | 0.859 |
| Max-IMT (mm) | 1.42 ± 0.46 | 1.36 ± 0.37 | 1.65 ± 0.43 | 0.003 |
Data are means ± standard deviation or n (%). Low, middle, and high variability are defined as the lowest (<8.29 mmHg), middle (8.29–10.99 mmHg), and highest (>10.99 mmHg) tertiles of the standard deviation of systolic blood pressure, respectively.
E, early ventricular filling velocity; A, late ventricular filling velocity; e’, early diastolic mitral annular velocity; LVMI, left ventricular mass index; max-IMT, maximum intima-media thickness.
aAnalysis of covariance.
Prevalence of diastolic dysfunction and carotid atherosclerosis according to the level of blood pressure variabilit
| Blood pressure variability | ||||||||
|---|---|---|---|---|---|---|---|---|
| Low variability | Middle variability | High variability | ||||||
| Crude OR | Adjusted OR a | Crude OR | Adjusted OR a | |||||
| n (%) | OR | n (%) | (95% CI) | (95% CI) a | n (%) | (95% CI) | (95% CI) a | |
| Diastolic dysfunction | ||||||||
| E/e’ <15 | 43 (89.6) | 41 (85.4) | 34 (70.8) | |||||
| E/e’ ≥15 | 5 (10.4) | 1 (reference) | 7 (14.6) | 1.47 (0.43–5.00) | 1.33 (0.36–4.92) | 14 (29.2) | 3.54 (1.16-10.81) | 2.71 (0.78–9.38) |
| Carotid atherosclerosis | ||||||||
| Max-IMT ≤1.5 mm | 30 (62.5) | 29 (60.4) | 15 (31.2) | |||||
| Max-IMT >1.5 mm | 18 (37.5) | 1 (reference) | 19 (39.6) | 1.09 (0.48–2.48) | 1.47 (0.53–4.08) | 33 (68.8) | 3.67 (1.58-8.54) | 4.93 (1.75–13.91) |
OR, odds ratio; CI, confidence interval; E/e’, early ventricular filling velocity/early diastolic mitral annular velocity; IMT, intima–media thickness.
aAdjusted for age, sex, baseline systolic blood pressure, use of antihypertensive drugs, and history of cardiovascular disease.